Macitentan*
-
API Product :
Macitentan*
-
CEP :
-
-
WCC :
-
-
Therapeutic Use :
Other cardiovascular products; Antihypertensives
-
Originator :
Actelion Pharmaceuticals Ltd.
-
CAS No. :
441798-33-0
-
Trade Name. :
OPSUMIT
-
Molecular Weight :
588.28 g/ mol
-
Molecular Formula :
C19H20Br2N6O4S
Application
Macitentan is used to treat high blood pressure in the lungs (pulmonary arterial hypertension). This condition is thought to be caused by increased levels of a certain natural substance (endothelin-1).
General Description
Macitentan (trade name Opsumit) is an endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH).[1] The other two ERAs marketed as of 2014 are bosentan and ambrisentan.[1] Macitentan is a dual ERA, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ETA and ETB.[1] However, macitentan has a 50-fold increased selectivity for the ETA subtype compared to the ETB subtype.